当前位置: 首页 >> 检索结果
4161. Interleukin-1 Blockade in Cardiac Sarcoidosis: A Pilot Study.
作者: Jordana Kron.;Thomas Crawford.;Frank Bogun.;Jennifer H Jordan.;Todd Koelling.;Huzaefah Syed.;Aamer Syed.;Thomas Iden.;Kelly Polly.;Emily G Federmann.;Kirsta Bray.;Sangeeta Lathkar-Pradhan.;Amy Ladd.;Virginia M Dickson.;Andrew Barron.;Anahita Tavoosi.;Rob Beanlands.;David Birnie.;Kenneth Ellenbogen.;Benjamin W Van Tassell.;W Gregory Hundley.;Antonio Abbate.
来源: Circ Arrhythm Electrophysiol. 2023年16卷5期e011869页 4162. Four-Dimensional Flow Magnetic Resonance Imaging Features of a Platypnea-Orthodeoxia Syndrome Caused by a Patent Foramen Ovale.
作者: Samuel Sitbon.;Phalla Ou.;Caroline Nguyen.;Carsten Ehmer.;Eric Garbarz.;Eric Brochet.;Adeline Fuchs.;Pierre Aubry.;Jeremie Abtan.
来源: Circ Cardiovasc Imaging. 2023年16卷7期601-603页 4163. Novel Approaches for the Diagnosis of Concealed Nodo-Ventricular and His-Ventricular Pathways.
作者: Satoshi Higuchi.;Edward P Gerstenfeld.;Henry H Hsia.;Christopher X Wong.;Reginald T Ho.;Patrick J Tchou.;Batel Nissan.;Ayelet Shauer.;Bernard Belhassen.;Melvin M Scheinman.
来源: Circ Arrhythm Electrophysiol. 2023年16卷5期e011771页
Confirming the presence and participation of concealed nodo-ventricular (cNV) or concealed His-ventricular (cHV) pathways in tachyarrhythmias is challenging. We describe novel observations to aid in diagnosing cNV or cHV pathways.
4164. Causes of Early Mortality After Catheter Ablation of Atrial Fibrillation.
作者: Min Choon Tan.;Pattara Rattanawong.;Suganya Karikalan.;Abhishek J Deshmukh.;Komandoor Srivathsan.;Luis R Scott.;Christopher J McLeod.;Samuel J Asirvatham.;Peter A Noseworthy.;Siva K Mulpuru.;Yong-Mei Cha.;Thomas M Munger.;Justin Z Lee.
来源: Circ Arrhythm Electrophysiol. 2023年16卷5期e011365页
Recognition of the causes of early mortality after atrial fibrillation (AF) catheter ablation is essential for the improvement of patient safety. This study sought to determine the causes of early mortality (≤90 days) after AF ablation.
4165. Use of a Pulmonary Artery Pressure Sensor to Manage Patients With Left Ventricular Assist Devices.
作者: Vinay Thohan.;Jacob Abraham.;Adam Burdorf.;Nasir Sulemanjee.;Brian Jaski.;Maya Guglin.;Francis D Pagani.;Himabindu Vidula.;David T Majure.;Rebecca Napier.;Thomas J Heywood.;Rebecca Cogswell.;Nicholas Dirckx.;David J Farrar.;Stavros G Drakos.; .
来源: Circ Heart Fail. 2023年16卷6期e009960页
Hemodynamic-guided management with a pulmonary artery pressure sensor (CardioMEMS) is effective in reducing heart failure hospitalization in patients with chronic heart failure. This study aims to determine the feasibility and clinical utility of the CardioMEMS heart failure system to manage patients supported with left ventricular assist devices (LVADs).
4167. Myocardial Injury Thresholds for 4 High-Sensitivity Troponin Assays in a Population-Based Sample of US Children and Adolescents.
作者: John W McEvoy.;Dan Wang.;Tammy Brady.;Olive Tang.;Chiadi E Ndumele.;Josef Coresh.;Robert H Christenson.;Elizabeth Selvin.
来源: Circulation. 2023年148卷1期7-16页
Myocardial injury is an important pediatric diagnosis. Establishing normative data from a representative pediatric sample is vital to provide accurate upper reference limits (URLs) for defining myocardial injury using high-sensitivity cardiac troponin.
4168. Heart Failure Across the Range of Mildly Reduced and Preserved Ejection Fraction in the United States.
作者: Stephen J Greene.;John A Spertus.;Wenxi Tang.;Amiee Kang.;Yue Zhong.;Michael C Myers.;Sophie Shen.;Jenny Jiang.;Xuejun Liu.;David R Steffen.;Marta G Viola.;G Michael Felker.
来源: Circ Heart Fail. 2023年16卷5期e010430页 4171. Elucidation of ALG10B as a Novel Long-QT Syndrome-Susceptibility Gene.
作者: Wei Zhou.;Dan Ye.;David J Tester.;Sahej Bains.;John R Giudicessi.;Carla M Haglund-Turnquist.;Kate M Orland.;Craig T January.;Lee L Eckhardt.;Kathleen R Maginot.;Michael J Ackerman.
来源: Circ Genom Precis Med. 2023年16卷2期e003726页
Long-QT syndrome (LQTS) is characterized by QT prolongation and increased risk for syncope, seizures, and sudden cardiac death. The majority of LQTS stems from pathogenic mutations in KCNQ1, KCNH2, or SCN5A. However, ≈10% of patients with LQTS remain genetically elusive. We utilized genome sequencing to identify a novel LQTS genetic substrate in a multigenerational genotype-negative LQTS pedigree.
4172. Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results.
作者: Ozan Dikilitas.;Alborz Sherafati.;Seyedmohammad Saadatagah.;Benjamin A Satterfield.;David C Kochan.;Katherine C Anderson.;Wendy K Chung.;Scott J Hebbring.;Zachary M Salvati.;Richard R Sharp.;Amy C Sturm.;Richard A Gibbs.;Robb Rowley.;Eric Venner.;Jodell E Linder.;Laney K Jones.;Emma F Perez.;Josh F Peterson.;Gail P Jarvik.;Heidi L Rehm.;Hana Zouk.;Dan M Roden.;Marc S Williams.;Teri A Manolio.;Iftikhar J Kullo.
来源: Circ Genom Precis Med. 2023年16卷2期e003816页
The implications of secondary findings detected in large-scale sequencing projects remain uncertain. We assessed prevalence and penetrance of pathogenic familial hypercholesterolemia (FH) variants, their association with coronary heart disease (CHD), and 1-year outcomes following return of results in phase III of the electronic medical records and genomics network.
4173. Correction to: Examination of Sexual Identity Differences in the Prevalence of Hypertension and Antihypertensive Medication Use Among US Adults: Findings From the Behavioral Risk Factor Surveillance System.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷4期e000116页
4174. Amputation After Endovascular Therapy With and Without Intravascular Ultrasound Guidance: A Nationwide Propensity Score-Matched Study.
作者: Nao Setogawa.;Hiroyuki Ohbe.;Hiroki Matsui.;Hideo Yasunaga.
来源: Circ Cardiovasc Interv. 2023年16卷4期e012451页
Intravascular ultrasound (IVUS) provides precise intravascular information during endovascular therapy (EVT). However, the clinical efficacy of IVUS in patients who undergo EVT remains unknown. The present study aimed to determine whether the use of IVUS-guided EVT is associated with better clinical outcomes in a real-world setting.
4175. Ischemia in Anomalous Aortic Origin of a Right Coronary Artery: Large Pediatric Cohort Medium-Term Outcomes.
作者: Tam T Doan.;Shagun Sachdeva.;Carlos Bonilla-Ramirez.;Dana L Reaves-O'Neal.;Prakash Masand.;Carlos M Mery.;Ziyad Binsalamah.;Jeffrey H Heinle.;Silvana Molossi.
来源: Circ Cardiovasc Interv. 2023年16卷4期e012631页
Anomalous aortic origin of a right coronary artery may cause myocardial ischemia and sudden death in the young. Data on myocardial ischemia or longitudinal outcomes are sparse in pediatric anomalous aortic origin of a right coronary artery population.
4177. Abnormal Mechanics Relate to Myocardial Fibrosis and Ventricular Arrhythmias in Patients With Mitral Valve Prolapse.
作者: Yasufumi Nagata.;Philippe B Bertrand.;Vinit Baliyan.;Jonathan Kochav.;Ruth D Kagan.;Kristian Ujka.;Hassan Alfraidi.;Antonia van Kampen.;Jordan E Morningstar.;Jacob P Dal-Bianco.;Serguei Melnitchouk.;Godtfred Holmvang.;Michael A Borger.;Reece Moore.;Lanqi Hua.;Razia Sultana.;Pablo Villar Calle.;Brian Yum.;J Luis Guerrero.;Tomas G Neilan.;Michael H Picard.;Jiwon Kim.;Francesca N Delling.;Judy Hung.;Russell A Norris.;Jonathan W Weinsaft.;Robert A Levine.
来源: Circ Cardiovasc Imaging. 2023年16卷4期e014963页
The relation between ventricular arrhythmia and fibrosis in mitral valve prolapse (MVP) is reported, but underlying valve-induced mechanisms remain unknown. We evaluated the association between abnormal MVP-related mechanics and myocardial fibrosis, and their association with arrhythmia.
4178. Empagliflozin Improves Left Atrial Strain in Patients With Type 2 Diabetes: Data From a Randomized, Placebo-Controlled Study.
作者: Kirsten Thiele.;Matthias Rau.;Julian Grebe.;Niels-Ulrik Korbinian Hartmann.;Ertunc Altiok.;Michael Böhm.;András P Keszei.;Nikolaus Marx.;Michael Lehrke.
来源: Circ Cardiovasc Imaging. 2023年16卷4期e015176页 4180. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
作者: Moritz J Hundertmark.;Amanda Adler.;Charalambos Antoniades.;Ruth Coleman.;Julian L Griffin.;Rury R Holman.;Hanan Lamlum.;Jisoo Lee.;Daniel Massey.;Jack J J J Miller.;Joanne E Milton.;Shveta Monga.;Ferenc E Mózes.;Areesha Nazeer.;Betty Raman.;Oliver Rider.;Christopher T Rodgers.;Ladislav Valkovič.;Eleanor Wicks.;Masliza Mahmod.;Stefan Neubauer.
来源: Circulation. 2023年147卷22期1654-1669页
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabolism are detectable in all HF phenotypes, and it was proposed that SGLT2i may improve energy production. The authors aimed to investigate whether treatment with empagliflozin leads to changes in myocardial energetics, serum metabolomics, and cardiorespiratory fitness.
|